Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus

Ooi, Cheow Peng; Ting, Tzer Hwu; Loke, Seng Cheong

doi:10.1002/14651858.cd011102

Cited by 3 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exogenous insulin is mainly used in patients with type 1 diabetes and type 2 diabetes poorly controlled with diet and oral anti-diabetic drug (OAD). Medium-acting insulin have the disadvantages of high variability, obvious peak effect, shorter duration, and high risk of hypoglycemia at night [15,16]. Long-acting insulin is needed so that patients can control their blood glucose with single injection only once a day [17].…”

Section: Discussionmentioning

confidence: 99%

Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection

Zeng

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Recombinant insulin Lisargine is a new type of insulin. In this study, we aimed to compare its pharmacodynamic (PD) and pharmacokinetic (PK) with Lantus. Methods The PD test was performed by exploring the effect of single administration on blood glucose of normal rats and STZ-induced diabetic rats, and the effect of multiple administrations on blood glucose of STZ-induced diabetic rats. Further PD tests include receptor affinity test, receptor autophosphorylation test and adipocyte glucose uptake test. Four IU and 8 IU per dog Lisargine was used for PK test, insulin was measured and area under curve (AUC) was calculated. Results With single injection, Lisargine 1.5 IU/kg had significant hypoglycemic effects at 1 and 2 h, similar to that of Lantus. Lisargine 5 IU/kg and 10 IU/kg lowered the blood glucose of STZ-induced diabetic rats at 1, 2, 4 & 6 h significantly. With multiple injections, Lantus lowered blood glucose at 2, 4 & 6 h, Lisargine 2.5 IU/kg, 5 IU/kg, and 10 IU/kg lowered blood glucose at 2 & 4 h significantly, compared with vehicle. There was no difference for receptor affinity test, receptor autophosphorylation test and adipocyte glucose uptake test between Lisargine and Lantus. The PK of Lisargine and Lantus of healthy Beagle dogs was very similar. Conclusions This animal study demonstrated that PK and PD of Lisargine and Lantus were similar, suggesting the bioequivalence of these products.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection

Zeng

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

show abstract

“…Ultra-long-acting insulin was defined as insulin with a clinical glucose lowering effect of more than 24 hours after subcutaneous injection in patients with DM. 13 This included glargine U300 and degludec. The exclusion criteria were as follows: pregnant women, non-adherence with medication refill, periodic laboratory investigations or follow up appointments in a clinic; use of systemic steroids, end-stage renal disease, patients who used pre-mixed insulin, or who used an insulin pump before or during the study period, and patients who received more than two types of basal insulin during the period of the study.…”

Section: Methodsmentioning

confidence: 99%

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients

WA¹,

BH²,

Alsabaan³

et al. 2022

DMSO

View full text Add to dashboard Cite

Purpose This research was intended to explore the effects of new-generation basal insulin (degludec U100 And glargine U300) versus long-acting basal insulin (glargine U100, detemir) on the incidence of diabetic ketoacidosis episodes and diabetes treatment measures. Patients and methods This is a cross-sectional, retrospective medical record analysis. The study population included adults with type 1 diabetes mellitus (DM) who were on the hospital records in 2020. Data were collected from 221 eligible participants through review of electronic medical records. Each record was scanned for basal insulin type, total daily insulin dose, diabetic ketoacidosis (DKA) occurrences, and glycated hemoglobin A1C (HbA1c) levels. Data were collected from 6 months before to 6 months after the initiation of ultra-long-acting insulin. Statistical analysis was conducted using R version 3.5.2. The normality of distribution for each independent variable was verified using Shapiro–Wilk tests. The independent paired t -test was used to compare insulin therapy measures between the two insulin regimens. The main outcome measures were the incidence of DKA episodes and clinical outcomes associated with diabetes. Results The HbA1c did not change significantly before and after ultra-long-acting insulin therapy was initiated (9.9 vs 9.8, respectively; P >0.05). Insulin total daily doses were significantly higher after shifting to ultra-long-acting insulin. Sub-analysis showed higher total daily insulin doses in glargine U300 users compared with degludec U100 users ( P =0.0021). However, basal insulin doses did not change after treatment with ultra-long-acting insulin. No statistically significant difference in DKA occurrences was found before and after the start of ultra-long-acting insulin treatment. Conclusion The frequency of DKA episodes was not affected by changing the treatment to ultra-long-acting insulin. Moreover, the results suggest that insulin dosage and types are not the only cause of uncontrolled diabetes. Additional efforts should be made to cover all factors affecting diabetes complication control.

show abstract

“…A Cochrane review is underway to assess the efficacy and safety of ultra-long acting insulin analogues relative to basal insulins. [ 8 ]…”

Section: Nsulin D Egludec In mentioning

confidence: 99%

Pediatric diabetes: Potential for insulin degludec

Kalra

Unnikrishnan

Sahay

2014

Indian J Endocr Metab

View full text Add to dashboard Cite

Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus

Cited by 3 publications

References 55 publications

Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection

Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients

Pediatric diabetes: Potential for insulin degludec

Contact Info

Product

Resources

About